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Abstract 
This study critically assessed the observable side effects of cisplatin (anti-tumor) drug in a Portulaca oleracea 
treated nephrotoxicized wistar rats. Twenty four albino female rats were grouped into four-groups A, B, C, & D. 
Group A served as the control group; group C and D were all nephrotoxicized using 2ml/kg cisplatin and treated 
with 400mg/kg and 800mg/kg doses of Portulaca oleracea methanolic extract respectively. Group B were 
nephrotoxicized but remained untreated. Significant Increase in serum creatinine (P<0.05) in group B rats 
showed presence of nephrotoxicity and results further showed recovery (significant decrease at P<0.05) in serum 
creatinine level of groups C &D rats due to the administration of portulaca oleracea. Physically observable 
features were examined in the rats at the 4th & 7th day of drug administration which showed the presence of side 
effects (ototoxicity, loss of appetite, black stool, dizziness, fever, etc) which were seen to be increasing with 
prolonged administration. This research posits seemingly untreatable side effect of cisplatin chemotherapy which 
increases with increased chemotherapy duration and decreased side effects in the combination of portulaca 
oleracea in cisplatin chemotherapy. 
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INTRODUCTION 
Cisplatin (CP) is a chemotherapy drug. It was the first member of a class of platinum-containing anti-cancer drug 
which reacts in vivo, binding to and causing crosslink of DNA which ultimately triggers apoptosis[22]. It is 
administered intravenously as short term infusion in normal saline for treatment of various types of cancers 
including sarcomas, some carcinomas ( eg. small cell lung cancer and ovarian cancers), lymphomas and germ 
cell tumors[16]. It is particularly effective against testicular cancer[17]. Chemotherapy for lymphoproliferative 
disease, leading to tumor lysis syndrome with uric acid and calcium phosphate crystal deposition, has also been 
associated with renal failure[7]. Cisplatin is accompanied by decrease in glomerular filtration rate (GFR), increase 
in blood urea nitrogen and serum levels of creatinine and tubular injury[12]. Nephrotoxicity is a dose limiting side 
effect of Cisplatin that can limit its use[18].  
Common neurological side effects of cisplatin include visual perception and hearing disorder which can occur 
soon after treatment begins [19,20]. Cisplatin is one of the most emetogenic chemotherapy agent showing nausea 
and vomiting as its side effects [22], ototoxicity, electrolyte disturbance, myelotoxicity, and hemolytic anemia[21]. 
Portulaca oleracea (purslane) extract used in the treatment of nephrotoxicity is a widespread weed ranked 8th 
most common plant in the world [14], has a long history of use for human food, animal feed and medicine. It is 
used in liver and kidney disorder, as an emollient, astringent and diuretic [10], depurative, anti-bacterial, anti-
scorbutic, and febrifuge[25]. It has been described as a ‘power food’ of the future because of its high nutritive and 
anti-oxidative properties[15]. 
 
MATERIAL AND METHOD 
Fresh aerial parts of PO was harvested, dried, finely grated and extracted using methanol in soxhlet apparatus. 
Twenty four female wistar rats were obtained, acclamatized for two weeks under standard housing condition, fed 
ad-libitum with water and standard rat chow. The rats were divided into four groups A-D. group A served as the 
control group; group B received only a single dose of cisplatin (2ml/kg), Group C and D were given cisplatin 
(2ml/kg) and were treated with 400mg/kg and 800mg/kg methanolic extract of portulaca oleracea respectively. 
Portulaca oleracea treatment was given two hours after cisplatin drug administration. Cisplatin drug was 
administered intraperitonially while the PO extract was administered orally. Physically observable changes and 
features were accessed during the 4th and 7th day of cisplatin administration. These side effects were divided into 
four groups based on convenience. The water consumption of the rats was also monitored before and after drug 
administration. The cisplatin side effects on the rats were observed before and after drug administration. The 
animals were anaesthetized after the 7th day of drug administration and 5ml of blood sample each were collected 
by cardiac puncture into centrifuge tubes. The serum was separated by centrifugation for twenty minutes at 
4000rpm and the serum creatinine level assessed using the Jaff’s method as modified by Ochei and kolhatka[13]. 
Journal of Biology, Agriculture and Healthcare                                                                                                                                www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol.4, No.8, 2014 
 
33 
The results were analyzed using SPSS (version 16.0) and the differences between mean and the main effects of 
the groups were determined by one way anova and the results expressed as mean value ± SD. P< 0.05 were seen 
to statistically significant. 
 
RESULTS 
Table 1.0 showing the serum creatinine level of wistar rats after drug administration 
GROUPS SERUM CREATININE (mg/dl) 
GROUP A                0.21± 0.01* 
GROUPB               0.61±0.00** 
GROUP C               0.39±0.04*** 
GROUP D               0.24±0.00*** 
*the serum creatinine level of the normal rats (untreated rats) were significantly lower (P<0.05) than all other 
groups. **There is a significant increase in serum creatinine (P<0.05) of Group B rats due to administration of 
cisplatin when compared to the other groups. ***There was a significant decrease (P<0.05) in the serum 
creatinine of groups C&D when compared to Groups A 
Table 2.0 showing the average water consumption of animals before and during drug administration 
GROUPS WATER CONSUMPTION  
(ML/DAY) BEFORE 
ADMINISTRATION 
WATER CONSUMPTION 
(ML/DAY) AFTER 
ADMINISTRATION 
A 30.00±2.00 29.00±1.41 
B 28.67±1.53 32.00±2.83 
C 29.00±1.00 22.00±2.83 
D 33.00±2.65 38.00±0.00 
The increase or decrease in the water consumption of the animals before or after the drug administration were 
not statistically significant (P<0.05) except group D that showed a statistically significant increase after drug 
administration when compared to the other groups. 
Table 3.0 showing the average body weight of animals before and after drug administration. 
GROUPS BODY WEIGHT (GRAMS) 
BEFORE ADMINISTRATION 
BODY WEIGHT (GRAMS) 
AFTER ADMINISTRATION 
A 150.60±11.07 167.23±13.12 
B 148.15±13.43 143.88±10.62 
C 152.03±18.91 174.98±4.20 
D 166.70±12.00 183.93±5.74 
There was a significant decrease in the average weight of rats in group B (P<0.05) when compared to rats in 
Group A. however, significant increase in the average weight was seen in rats of groups  A, C and D when 
compared with group B (P<0.05). 
Summary of group 1 side effects observed at day 4 and 7 during drug administration (tables 4.0&5.0) 
Group A showed none of the group I side effects. Both fast breathing and blurred vision were not observed in 
any of the groups at all at both 4th and 7th day of drug administration. Wheezing manifested only in groups C & 
D at day 7 of side effect assessment. There were signs of moderate troubled walking in group D rats on the 4th 
day (which disappeared at day 7) and in group B in the 7th day. All the treated groups except A were seen to be 
moderately tired at day 4 except group C with group D being severely tired at day 7 of drug administration. 
Table 4.0 Observable physical features   at day 4 during drug administration – Group 1 side effects 
GROU
PS 
DIZZINESS/TIRED
NESS 
TROUBL
ED 
WALKIN
G 
WHEEZI
NG 
BLURR
ED 
VISION 
FEVER/SHIVER
ING 
FAST 
BREATHI
NG 
A - - - - - - 
B + - - - + - 
C - - - - - - 
D + + - - - - 
KEY  
 
 
 
  
+ MODERATE 
++ SEVERE 
- ABSENT 
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Table 5.0 Observable physical features   at day 7 during drug administration – Group 1 Side effects 
GROU
PS 
DIZZINESS/TIRED
NESS 
TROUBL
ED 
WALKIN
G 
WHEEZI
NG 
BLURR
ED 
VISION 
FEVER/SHIVER
ING 
FAST 
BREATHI
NG 
A - - - - - - 
B + + - - - - 
C + - + - - - 
D ++ - + - - - 
KEY 
 
 
 
Summary of group 2 side effects observed at day 4 and 7 during drug 
administration (tables 6.0&7.0) 
Group 2 side effects were not seen at all in groups except for group D rats that showed moderate doughiness at 
both the 4th and 7th day. 
Table 6.0 Observable physical features   at day 4 during drug administration – Group 2 side effects 
GROUPS PIN POINT 
REDNESS 
MOUTH/LIP 
SORE 
DOUGHINESS/SPRINGBACK PALE 
TOES 
AND 
EARS 
FACE AND 
MUSCLE 
SWELLING 
A - - - - - 
B - - - - - 
C - - - - - 
D - - + - - 
KEY 
 
 
 
 
 
Table 7.0 Observable physical features   at day 7 during drug administration – Group 2 side effects 
GROUPS PIN POINT 
REDNESS 
MOUTH/LIP 
SORE 
DOUGHINESS/SPRINGBACK PALE 
TOES 
AND 
EARS 
FACE AND 
MUSCLE 
SWELLING 
A - - - - - 
B - - - - - 
C - - - - - 
D - - + - - 
KEY 
 
 
 
Summary of group 3 side effects observed at day 4 and 7 during drug 
administration (tables 8.0 & 9.0) 
No signs of bloody urine were seen in all groups; at day 7, moderate damper bedding were seen in groups B and 
D. moderate  black and bloody feces were observed in group B and C rats on the 4th day of drug administration 
and groups B, C, and D on the 7th day. No trace of vaginal discharge were seen on the 7th day 
  
+ MODERATE 
++ SEVERE 
- ABSENT 
+ MODERATE 
++ SEVERE 
- ABSENT 
+ MODERATE 
++ SEVERE 
- ABSENT 
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Table 8.0 Observable physical features   at day 4 during drug administration – Group 3 side effects 
GROUPS BLOODY URINE DAMPER 
BEDDING 
BLACK AND 
BLOODY FECES 
VAGINAL 
DISCHARGE 
A - - - - 
B - - + - 
C - - + - 
D - + - - 
 
KEY 
 
 
 
 
 
Table 9.0 Observable physical features   at day 7 during drug administration – Group 3 side effects 
GROUPS BLOODY URINE DAMPER 
BEDDING 
BLACK AND 
BLOODY FECES 
VAGINAL 
DISCHARGE 
A - - - - 
B - + + + 
C - - + - 
D - + + - 
KEY 
 
 
 
Summary of group 4 side effects observed at day 4 and 7 during drug 
administration ( tables 10.0&11.0) 
All the treated groups showed moderate ototoxicity at both 4th & 7th day of drug administration. Group D showed 
moderate hunched over position on the 4th day of administration only. Group B showed severe loss of appetite at 
both 4th and 7th day and group C & D showed moderate appetite loss on day 4 of drug administration which were 
reversed on day 7.  Death occurred in group B rats after the 7th day of drug administration.  
 
Table 10.0 Observable physical features   at day 4 during drug administration – Group 4 symptoms 
GROUPS LOSS OF 
APPETITE 
OTOTOXICITY HUNCHED 
OVER 
DEATH 
A - - - - 
B ++ + - - 
C + + - - 
D + + + - 
KEY 
 
 
 
Table 11.0 Observable physical features   at day 7 during drug administration – 
Group 4 symptoms 
GROUPS LOSS OF 
APPETITE 
OTOTOXICITY HUNCHED 
OVER 
DEATH 
A - - - - 
B ++ + - + 
C - + - - 
D - + - - 
KEY 
 
 
 
 
 
  
+ MODERATE 
++ SEVERE 
- ABSENT 
+ MODERATE 
++ SEVERE 
- ABSENT 
+ MODERATE 
++ SEVERE 
- ABSENT 
+ MODERATE 
++ SEVERE 
- ABSENT 
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DISCUSSION 
Drugs cause approximately 20 percent of community- and hospital acquired episodes of acute renal failure[1,2,3]. 
Among older adults, the incidence of drug-induced nephrotoxicity may be as high as 66 percent[4]. Compared 
with 30 years ago, patients today are older, have a higher incidence of diabetes and cardiovascular disease, take 
multiple medications, and are exposed to more diagnostic and therapeutic procedures with the potential to harm 
kidney function[5]. A lthough renal impairment is often reversible if the offending drug is discontinued . the 
condition can be costly and may require multiple interventions, including hospitalization[6].  Cisplatin is the most 
commonly used antitumor drug in the clinic and has been implicated to cause nephrotoxicity as its major side 
effect[12],hence its use in this research. Major cisplatin-induced side effects including nephrotoxicity and 
hepatotoxicity are popularly known and widely researched on which sometimes seem to be chronic in nature. 
However, this research focused on the physically observable side effects and its possible attenuation with a 
combined Portulaca oleracea extract treatment. About 21 physically observable side effects were evaluated in 
this research. 
Cisplatin drug administered was able to cause a significant nephrotoxicity as evidenced by increased serum 
creatinine (P<0.05) in group B as compared to group A (table 1.0). this effect seems to be attenuated by 
portulaca oleracea extract in groups C and D which showed a significantly decreased serum creatinine (P<0.05) 
when compared to group B. this agrees with the research by Gholamreza Karimi et al 2010[11] on the nephro-
protective effect of aqueous and  ethanolic extracts of portulaca oleracea on cisplatin-induced renal toxicity. 
Nephrotoxicity of cisplatin is usually associated with their accumulation in renal cortex, dependent upon their 
affinity to kidney and on kinetics of drug trapping process [9]. Cisplatin induced oxidative stress can activate 
some protein kinases which sensitizes the injured cell to apoptosis [11]. 
Cisplatin showed no significant effect on the water consumption of the rats as seen in the group B ( the cisplatin 
control group) when compared to the normal control group ( group A ). The combination treatment with cisplatin 
and portulaca oleracea extract in groups C and D caused a significant decrease and increase ( P< 0.05) in average 
water consumption respectively when compared to the control group and cisplatin group ( table 2.0). the 
opposite significant effects seen in the treated groups is suspected to be due to the dose-effect relationship of 
portulaca extract given to the groups as group B showed no significant effect (P<0.05). 
The effect of cisplatin on the average body weight was also observed; the cisplatin control group showed a 
significant decrease (P<0.05) in average body weight when compared to the other groups (table 3.0) 
The physically observable side effects observed in this research which were grouped into four were not present 
in the control group showing their incidence in other groups to be as a result of cisplatin. Cisplatin side effects 
have been noted to be moderate or more severe; may get better or worse through the course of treatment or more 
side effect may develop as the course goes on[24]. 
In group 1 side effects (tables 4.0&5.0), fast breathing and blurred vision was not observed at both days of 
assessment during drug administration. Fever, present only in cisplatin on the 4th day was inconstant as it were 
absent on the next day of assessment. Wheezing as a side effect was observed to show a slow onset in the 
portulaca oleracea treated group (group C &D) by its appearance in the 7th day of drug administration. This slow 
onset have received suppression by the anti-oxidative property of portulaca oleracea[15]. Cisplatin has the ability 
to lower WBC and platelet count hence increasing the risk of infections  like fever, chills, pain or bleeding [8]. 
Troubled walking noticed in group D rats were seen to disappear in the 7th day of assessment (table 5.0); this 
may be as a result of the higher dose of portulaca oleracea extract administered or damage to certain nerves in 
the body causing peripheral neuropathy resulting to troubled walking[8]. 
Groups B & D showed moderate dizziness at the first assessment (table 4.0) and only D showed severe tiredness 
during the 7th day of drug administration. Dizziness, spotted redness, fast breathing and swelling of the face are 
seen as allergic reactions and starts immediately after treatment [23]. However, based on this research finding, this 
is true with dizziness only (Tables 4.0 & 5.0); the allergic side effects have been described as a rare side effect [8]. 
Group 2 side effects were not seen at all in all groups except for group D rats that showed moderate doughtiness 
at both 4th and 7th (table 6.0&7.0), suggesting an association between dizziness (group 1 side effect) and 
doughtiness which were all shown by group D. 
In group 3 side effects, there were no signs of bloody urine in all groups but damper beddings were seen in 
groups B (on the 7th day) and D (on the 4th and 7th day) after drug administration (tables 8.0 & 9.0). This finding 
shows a correlation between damper bedding and average water consumption (table 2.0) as there was a 
significant increase (P<0.05) in average water consumption of Group D rats who compared with other groups to 
compensate for the increased urine output/damper beddings (tables (8.0&9.0). All the groups except for A shared 
presence of black and bloody feces either on the 4th or 7th day. Group B rats showed traces of vaginal discharge 
on the 7th day of drug administration (table 9.0) 
In the grouping side effects, ototoxicity, which is a major side effect of cisplatin and were noticed at a moderate 
level in groups B, C & D, each showing early onset (on the 4th day of drug administration) continuing till the 7th 
day (tables 10.0 & 11.0).hearing disorder and visual perception are all neurological side effects[19,20] and can 
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occur soon after treatment begins. The neurological side effects has been said to be caused by non-competitive 
inhibition of an archetypal membrane –bound mechanosensitive sodium-hydrogen ion transporter known as 
NHE-1 by cisplatin. This transporter is mostly found on the cells of the PNS near ocular and aural stimuli 
receiving centers. This inhibition is said to be dose-dependent and reversible[19]. Complete hearing loss may be 
caused by ciplatin’s ability to bind melanin in the stria vascularis[22]. Group D showed a hunched over position 
on the 4th day ( table 10.0; this supports and shows a relationship between the earlier side effects( dizziness and 
doughtiness)and hunched over position  seen in this same group – ( tables 4,5,6&7). All groups except A showed 
loss of appetite during drug administration but while groups C & D showed a moderate loss, group B was severe 
hence showing the chronic effect of cisplatin drug. This agrees with the average body weight which was 
significantly decreased (P<0.05) when compared to other groups (table 3.0). This supports the finding on 
cisplatin induced loss of appetite which is said to occur few days after cisplatin treatment. Death was seen to 
occur in group B which received only cisplatin drug; two out of the six rats used for the group died after the drug 
administration showing a severe and terminal side effect of cisplatin when not in combination with its side-effect 
reducing drug like portulaca oleracea. 
 
CONCLUSION 
This research work posits that portulaca oleracea extract or any other phytochemically equivalent drug can be a 
good combination with cisplatin in chemotherapy to reduce its side-effect. 
However, cisplatin side effect has been discovered not to have a definite pattern or association; it can be 
moderate or severe and can increase or decrease during the course of treatment. Ototoxicity (loss of hearing) has 
been noted to be a major side effect of cisplatin which among others may or may not be reversed even after 
cisplatin chemotherapy. Further research should be carried out on the systemic side effects of cisplatin and a 
wholistic combination therapy possibility for more reduced side effects in cisplatin chemotherapy. 
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